• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Zydus Cadila gets tentative US FDA approval for Carbidopa and Levodopa extended-release capsules

expresspharmaAugust 03, 2020

Tag: Zydus Cadila , FDA , carbidopa , levodopa , Parkinson

Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

This medication is used to treat the symptoms of Parkinson’s disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 295 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.


Previous:Sanofi, GSK to supply 100 mn doses of COVID-19 vaccine to US, in talks with EU for 300 mn doses

Next:GAVI’s new drive for COVID-19 vaccine access in LMIC countries includes India

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Zydus Cadila gets tentative US FDA approval for Carbidopa and Levodopa extended-release capsules | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

China Nature Levodopa L Dopa Price 59-92-7 L-dopa Powder Mucuna Pruriens Extract

China Nature Levodopa L Dopa Price 59-92-7 L-dopa Powder Mucuna Pruriens Extract
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Vitamine B12 (FDA)

Vitamine B12 (FDA)
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
  Levodopa

  Levodopa
Carbidopa EP Impurity B

Carbidopa EP Impurity B
CARBIDOPA

CARBIDOPA
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service